PHÂN TÍCH KẾT QUẢ LÂM SÀNG VÀ BIẾN CỐ BẤT LỢI TRÊN NGƯỜI BỆNH COVID-19 ĐƯỢC SỬ DỤNG THUỐC REMDESIVIR TẠI BỆNH VIỆN ĐA KHOA QUỐC TẾ VINMEC

Abstract

Remdesivir is an antiviral drug that has been approved for the treatment of hospitalized COVID-19 patients in many countries, including Vietnam. However, clinical data of remdesivir is lacking in Vietnam. This study was carried out to investigate clinical outcome and safety of remdesivir in the treatment of COVID-19 in Vietnam. A retrospective observational study was performed in all hospitalized COVID-19 patients 12 years of age and older treated with at least one dose of remdesivir from 10 August 2021 to 10 September 2021 at Vinmec Central Park Hospital. The clinical outcome was measured by the WHO 6-point scale, mechanical ventilation at day 14, and 28-day mortality. The safety of remdesivir was evaluated based on the 2017 AIDS scale. Results: 152 patients were enrolled in this study with more than 50% had at least one comorbidity, mainly cardiovascular diseases or diabetes. Patients was treated with remdesivir at median 6 days after onset. 55.7% patients had significant clinical improvement at day 11. In this study, 14.6% of patients received invasive mechanical ventilation on day 14. The 28-day mortality was 12.5%. The most commonly reported adverse events included elevation of liver enzymes (29.6%), hypokalemia (26.3%), decreased glomerular filtration rate (17.8%), bradycardia (11.2%) and prolongation of prothrombin time (15.1%). Risk factor for poor outcome were advanced age, having at least one comorbidity, low ROX score, requirement of HFNC, non-invasive ventilation or invasive mechanical ventilation; elevated PCT, D-Dimer, ferritin; decreased lymphocyte count at baseline.